Tadashi Matsushita

Nagoya, 4668560, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 172 publications

Adductome-Based Identification of Novel Oxidized Phospholipid-Lysine Adducts Formed in Low-Density Lipoprotein.

Adductome-Based Identification of Novel Oxidized Phospholipid-Lysine Adducts Formed in Low-Density Lipoprotein.

Journal: Biochemistry

Published: May 16, 2026

Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors.

Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors.

Journal: The New England journal of medicine

Published: April 29, 2026

Five-Year Longitudinal Changes in Treatment Strategies and Clinical Outcomes in Adults With Haemophilia: The ADVANCE Japan Cohort Study.

Five-Year Longitudinal Changes in Treatment Strategies and Clinical Outcomes in Adults With Haemophilia: The ADVANCE Japan Cohort Study.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: April 15, 2026

Cardiovascular risk scores estimate arterial thrombotic risk in aging adults with hemophilia in the ADVANCE Japan cohort.

Cardiovascular risk scores estimate arterial thrombotic risk in aging adults with hemophilia in the ADVANCE Japan cohort.

Journal: Blood advances

Published: March 23, 2026

Concizumab in patients with hemophilia A or B without inhibitors: 56-week cutoff results of the phase 3 explorer8 study.

Concizumab in patients with hemophilia A or B without inhibitors: 56-week cutoff results of the phase 3 explorer8 study.

Journal: Blood advances

Published: January 30, 2026

Concizumab in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 study.

Concizumab in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 study.

Journal: Blood advances

Published: January 30, 2026

An exploratory plasma-based functional assay for phenotypic characterization of fibrinolysis in dysfibrinogenemia.

An exploratory plasma-based functional assay for phenotypic characterization of fibrinolysis in dysfibrinogenemia.

Journal: Research and practice in thrombosis and haemostasis

Published: January 19, 2026

Antithrombotic Therapy on Antithrombin Resistance in a Mouse Model.

Antithrombotic Therapy on Antithrombin Resistance in a Mouse Model.

Journal: Arteriosclerosis, thrombosis, and vascular biology

Published: January 08, 2026

Denecimig (Mim8) prophylaxis once-every-2-weeks for hemophilia A with or without inhibitors - 26-week results from FRONTIER.

Denecimig (Mim8) prophylaxis once-every-2-weeks for hemophilia A with or without inhibitors - 26-week results from FRONTIER.

Journal: Blood advances

Published: December 19, 2025

Real-World Use of Emicizumab in Patients With Acquired Haemophilia A: An Interim Safety Analysis of a Large-Scale Post‑Marketing Surveillance Study.

Real-World Use of Emicizumab in Patients With Acquired Haemophilia A: An Interim Safety Analysis of a Large-Scale Post‑Marketing Surveillance Study.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: December 17, 2025

A cohort study on cardiovascular diseases in adults with hemophilia: an interim subanalysis on comorbidities and medication from ADVANCE Japan

A cohort study on cardiovascular diseases in adults with hemophilia: an interim subanalysis on comorbidities and medication from ADVANCE Japan

Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology

Published: December 07, 2025

Spatiotemporal dynamics and ossification of podoplanin-positive cells in the developing femur.

Spatiotemporal dynamics and ossification of podoplanin-positive cells in the developing femur.

Journal: Scientific reports

Published: August 15, 2025

Showing 1-12 of 172

Last Updated: 09/26/2026